Navigation Links
Telik Announces Presentation at American Society of Hematology Annual Meeting
Date:11/10/2010

PALO ALTO, Calif., Nov. 10, 2010 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today it will report data from the Phase 2 randomized multicenter study of Telintra® (ezatiostat HCl) tablets in the treatment of patients with Myelodysplastic Syndrome at the 52nd Annual Meeting of the American Society of Hematology in Orlando, FL.Details of the presentation are as follows:Abstract #2910 - Myelodysplastic Syndromes: Poster II; Sunday, December 5, 2010, 6:00-8:00 pm EST; Orange County Convention Center, Hall A3/A4Title:  "Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog, Glutathione-S-transferase P1-1 (GSTP1-1) Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)."  Raza, A., Galili, N., Smith, S., et al.About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidates in clinical development are Telintra, a modified glutathione analog for the treatment of MDS and Severe Chronic Neutropenia (SCN), and Telcyta®, a cancer activated prodrug for the potential treatment of advanced non-small cell lung cancer and ovarian cancer.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Telik Announces Third Quarter 2010 Financial Results
2. Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects
3. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
4. Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
5. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
6. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
7. Telik Announces Third Quarter 2009 Financial Results
8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
9. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
10. Telik Announces Presentation at ASCO Annual Meeting
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), the ... company overview at the BMO Capital Markets Prescriptions for Success Healthcare ... . A live webcast of the presentation will ... website.  The replay will be available within 48 hours and will ... ...
(Date:12/6/2016)... , Dec. 6, 2016  Licenders is bringing their 100% all-natural ... location in Park Slope at 203 13 th Street was ... clientele. "Our goal is to ease parents, ... are designed to get children right back to class without skipping ... all natural and safe for the whole family," Licenders President ...
(Date:12/6/2016)... , Dec. 6, 2016 Homozygous ... 2016 Summary Global Markets Direct,s ... Homozygous Familial Hypercholesterolemia (HoFH) – Pipeline Review, ... Homozygous Familial Hypercholesterolemia (HoFH) (Metabolic Disorders) pipeline ... genetic disorder which is caused due to ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 , ... ... “Canine Filamentous Dermatitis Associated with Borrelia Infection” reveals that a ... published in the prestigious Journal of Veterinary Science & Medical Diagnosis. , Morgellons ...
(Date:12/7/2016)... ... , ... Facial plastic surgeon, Dr. John D. Rachel of Timeless You™ ... to two local organizations: North Chicago Animal Control and Friends and Our House of ... of authorized and trained volunteers who support rescued animals held in the City of ...
(Date:12/7/2016)... ... 07, 2016 , ... 1105 Media’s Live From program has ... Awards competition. Live From won in the Use of Social Media category. The ... projects undertaken by the media industry’s most innovative marketing professionals. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... Gensuite is ... Awards under the Best New Product Launch category. Gensuite’s entry on their EZ ... , BOC Global Events & Training Group is a professional event and training ...
(Date:12/7/2016)... ... ... Road To Restoration”: an informative and enlightening book for those who believe that ... “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, seventy-one-year-old ... you could reach out for, and grab, on the old carousels. If you ...
Breaking Medicine News(10 mins):